Bezafibrate, a peroxisome proliferator-activated receptor α agonist, decreases circulating CD14(+)CD16(+) monocytes in patients with type 2 diabetes
| Autor: | Tomoko Terasawa, Atsushi Momobayashi, Maiko Fukushima, Toshihiko Inukai, Yoshimasa Aso, Kyoko Omori |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty CD14 Lipopolysaccharide Receptors Peroxisome proliferator-activated receptor Gene Expression chemical and pharmacologic phenomena CD16 GPI-Linked Proteins Peripheral blood mononuclear cell Monocytes Proinflammatory cytokine Translational Research Biomedical immune system diseases Physiology (medical) Internal medicine Glucose Intolerance medicine Humans PPAR alpha RNA Messenger chemistry.chemical_classification Bezafibrate Chemistry Biochemistry (medical) Receptors IgG Public Health Environmental and Occupational Health virus diseases Interleukin hemic and immune systems General Medicine Middle Aged Endocrinology Cross-Sectional Studies Diabetes Mellitus Type 2 Cytokines Tumor necrosis factor alpha Female Inflammation Mediators medicine.drug |
| Zdroj: | Translational research : the journal of laboratory and clinical medicine. 165(2) |
| ISSN: | 1878-1810 |
| Popis: | CD14(+)CD16(+) monocytes are proinflammatory cells that produce tumor necrosis factor and interleukin (IL)-1β. The number of circulating CD14(+)CD16(+) monocytes is increased in patients with chronic renal failure or coronary artery disease. We investigated the effect of bezafibrate, a peroxisome proliferator-activated receptor α agonist, on circulating CD14(+)CD16(+) monocytes in patients with type 2 diabetes. Using cells isolated from type 2 diabetic subjects, we also examined the in vitro expression of CD16 messenger RNA (mRNA) by mononuclear cells (MNCs) exposed to bezafibrate. The percentage of CD14(+)CD16(+) monocytes among all CD14(+) monocytes was significantly higher in subjects with impaired glucose tolerance (P 0.01) or type 2 diabetes (P 0.05) than in those with normal glucose tolerance. The percentage of CD14(+)CD16(+) monocytes was significantly lower in patients with type 2 diabetes who were taking bezafibrate (400 mg/d) than in patients not taking it (P 0.01). Treatment with bezafibrate for 12 weeks significantly reduced the percentage of circulating CD14(+)CD16(+) monocytes from 45.4 ± 25.2% to 38.3 ± 21.8% (P = 0.0144). In an in vitro study, the expression of CD16 mRNA by MNCs from 6 diabetic subjects was decreased after 24 hours of treatment with 10 μg/mL of bezafibrate (P 0.05). Expression of IL-1β mRNA by MNCs was also decreased after 24 hours of treatment with 10 μg/mL of bezafibrate, whereas the IL-1β level in the culture supernatant was significantly decreased after treatment of MNCs with either 1 or 10 μg/mL of bezafibrate. In conclusion, bezafibrate decreased circulating CD14(+)CD16(+) monocytes in patients with type 2 diabetes, probably by inhibiting the expression of CD16 mRNA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect